Afatinib slows relapse in NSCLC
An investigational oral drug delayed disease relapse for nearly a year in some patients with advanced non-small cell lung cancer (NSCLC).
An investigational oral drug delayed disease relapse for nearly a year in some patients with advanced non-small cell lung cancer (NSCLC).
Latest study says regular follow-up positive. Scientist say there is an urgent need for research into all aspects of follow-up care in lung cancer. The study presented in… read more.
Like special-forces troops laser-tagging targets for a bomber pilot, tiny particles that can be imaged three different ways at once have enabled Stanford University School of Medicine scientists… read more.
Japanese have higher vulnerability to certain lung cancers. Previous research has shown that Asian patients with lung cancer are more likely to harbor epidermal growth factor receptor (EGFR)… read more.
A University of Miami study shows that women with non-metastatic breast cancer who are physically active and receive stress management intervention during treatment may reduce depression and lessen… read more.
Loyola researchers are reporting surprising findings about a molecule that helps ramp up the immune system in some cases and suppress it in others. The finding eventually could… read more.
Tailored, web-based intervention helped women understand options. When women at high risk of breast cancer viewed a customized web-based decision guide about prevention options, they were more likely… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.